Italia markets closed

Affimed N.V. (0HL9.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,1750+0,0930 (+4,47%)
Alla chiusura: 02:58PM BST
Schermo intero
Chiusura precedente2,0820
Aperto2,1750
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno2,1750 - 2,1750
Intervallo di 52 settimane2,1750 - 2,1750
Volume100
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)2,30
Rapporto PE (ttm)N/D
EPS (ttm)-0,6590
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022

    Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable disease was observed in 10 of 27 evaluable patients in an unselected patient populationComprehensive pharmacodynamic studies indicate the activation of the innate as well as the adaptive immune systemWell managed safety profile HEIDELBERG, Germany, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology com

  • GlobeNewswire

    Affimed to Present at Upcoming Investor Conferences

    HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the Company’s management will participate in the following investor conferences during the month of September 2022. 2022 Wells Fargo Healthcare Conference (September 6-9, 2022)Date: Wednesday, September 7, 2022Presentation Time: 3:10 p.m. Eastern Dayli

  • GlobeNewswire

    Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress

    AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated data at a scientific conference in the fourth quarter of 2022AFM24: Studies continue to enroll; data updates expected at scientific conferences in the second half of 2022AFM28: Following interactions with FDA, strategic decision to focus early clinical development in non-U.S. jurisdictions; clinica